索拉非尼对中晚期肝细胞癌患者近期生活质量的影响  

Improvement of Sorafenib on Recent Quality of Life for Patients with Terminal-stage Hepatocellular Carcinoma

作　　者：徐爱兵[1] 沈茜[1] 田思源[1] 谭清和[1] 

机构地区：[1]南通市肿瘤医院肿瘤内科,江苏南通226361

出　　处：《肿瘤防治研究》2013年第12期1187-1189,共3页Cancer Research on Prevention and Treatment

摘　　要：目的研究索拉非尼治疗三月后对中晚期肝细胞癌患者生活质量的影响。方法运用EORTC QLQ-C30量表评定36例口服索拉非尼治疗患者的生活质量,分析比较患者治疗前与治疗后3月生活质量的变化。结果 患者在躯体功能、疲倦、恶心呕吐、疼痛、便秘、腹泻及经济方面的评分,差异有统计学差异(P<0.05),总体生活质量无明显变化。结论索拉非尼作为分子靶向治疗新药,不仅可延长肝细胞癌患者的生存期,且近期生活质量无明显下降,耐受性较好。Objective To explore the improvement of sorafenib treatment on the recent quality of life for patients with terminal-stage hepatocellular carcinoma after three months. Methods We investigated the quality of life of 36 patients with oral sorafenib by the Quality of Life Questionnaire-C30（QLQ-C30） V3.0 of EORTC. The quality of life before and 3 months after the treatment was analyzed. Results There were significant difference among physical status, fatigue, nausea and vomiting, pain, constipation, diarrhea and economic difficulties（P〈0.05） but the overall quality of life had no obvious improvement. Conclusion Sorafenib might prolong the survival of HCC patients with well tolerance and without decline of quality of life.

关 键 词：索拉非尼 中晚期肝细胞癌 生活质量 

分 类 号：R735.7[医药卫生—肿瘤]